/PRNewswire/ Sensible Diagnostics, Inc., a diagnostics company that has developed a real-time PCR point-of-care (POC) diagnostic platform which yields.
PathogenDx Launches Breakthrough Clade Variant Testing and Secures Phase Two Funding as NIH Aims to Increase Capabilities for Viral Mutation Screenings
News provided by
Share this article
Share this article
SCOTTSDALE, Ariz., March 3, 2021 /PRNewswire/ PathogenDx, Inc., an Arizona based technology company which has developed a multiplexed microarray DNA-based pathogen testing platform, announced today the launch of their Clade Variant Adaptive Surveillance (CVAS) technology to identify SARS-CoV-2 variants in as little as four hours. PathogenDx has also entered phase two funding under the
Rapid Acceleration of Diagnostics (RADx) Tech program. The additional funding will be used to support Clade Variant Array screening nationally, initially as an RUO (research use only) release, as well as expand pooled COVID-19 testing with its Detect-Rv test kits for schools, businesses and communities nationwide.